Wells Fargo raised the firm’s price target on BridgeBio (BBIO) to $84 from $76 and keeps an Overweight rating on the shares. The firm likes the setup for shares, as it thinks there is likely upside to Attruby estimates in 2026, potential to gain clarity on Tafamidis Gxs, which should remove a key overhang, and a high probability of success Phase 3 read out for infigratinib in achondroplasia in early 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio presents data from ATTRibute-CM study on acoramidis
- BridgeBio price target raised to $77 from $76 at JPMorgan
- BridgeBio price target raised to $100 from $55 at Goldman Sachs
- BridgeBio Pharma’s Earnings Call Highlights Success and Challenges
- BridgeBio price target raised to $80 from $66 at Truist